Amplia Therapeutics CEO outlines 2023 milestones
Melbourne, Victoria –Information Direct– Amplia Therapeutics Ltd
Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks with Proactive following his transfer into the management position late final 12 months. Amplia is an Australian pharmaceutical firm advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for most cancers and fibrosis. FAK is an more and more vital goal in most cancers and Amplia has a specific growth focus in fibrotic tumours corresponding to pancreatic and ovarian cancers.
Contact Particulars
Proactive Buyers
Jonathan Jackson
+61 413 713 744
View supply model on newsdirect.com: https://newsdirect.com/news/amplia-therapeutics-ceo-outlines-2023-milestones-938374502